Evereden, the premium skin care brand founded by dermatologists from Stanford University and Harvard University, has raised $32 million in Series C funding. Resources will be used to scale expansion into new markets and sales channels and strengthen in-house research and development. In 2022, Evereden will deepen its presence in retail, specifically by launching globally in select markets at Sephora. Currently, Evereden makes 38 SKUs across five categories including baby, kids, mom, SPF and targeted solutions/medical skin care. The company has realized 350 percent year over year growth; forecasts expect the new funding will keep it on this accelerated growth path.

“Evereden has created a category of one in the skin care space by pairing innovation inspired by luxury beauty for families everywhere,” said Richard Lim, founder and Managing Director of GSR Ventures.

The company’s Kids Line, which launched six months ago, already comprises nearly 20 percent of Evereden’s total revenue.

“Our ability to grow and scale quickly is tied closely to our in-house R&D and product development capabilities,” noted Evereden Co-Founder and CEO Kimberley Ho, “We are motivated to continue to create and deliver products that families are excited to use at a pace that keeps up with the demand.”

All of Evereden’s product formulations are developed with help from dermatologists and moms that make up its Moms in Medicine team, including Evereden Chief Scientific Officer, Head of Pediatric Dermatology, Stanford Medical School Dr. Joyce Teng, MD, PhD; Evereden Scientific Officer, Professor of Dermatology, Harvard Medical School Dr. Sarina Elmariah, MD, PhD; and Evereden Scientific Officer, Instructor of Dermatology, Harvard Medical School Dr. Rebecca Hartman, MD, PhD.